Dark

COGT
Cogent Biosciences, Inc. Common Stock
stock NASDAQ

At Close

Aug 4, 2026 3:59:53 PM EDT

42.84USD+10.242%(+3.98)4,748,565

0.00Bid 0.00Ask 0.00Spread

Pre-market

Aug 4, 2026 9:28:00 AM EDT

40.12USD+3.242%(+1.26)493

After-hours

Aug 4, 2026 4:40:30 PM EDT

42.84USD0.000%(0.00)484,112

OverviewOptionsHistoricalExchangesShortsNews

Jan 5, 2022

07:10AM EST Cogent Biosciences To Advance APEX, SUMMIT And PEAK Clinical Trials RTTNews

07:01AM EST Cogent Biosciences Provides 2022 Corporate Guidance PR Newswire

Nov 22, 2021

07:01AM EST Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare PR Newswire

Nov 10, 2021

07:36AM EST Cogent Biosciences Says Ended Q3 With $202.9M In Cash Benzinga

07:14AM EST Cogent Biosciences Q3 Net Loss $19.1 Mln Vs Loss Of $50.0 Mln Last Year RTTNews

07:02AM EST Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 PR Newswire

Nov 5, 2021

01:05PM EDT HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $31 Benzinga

Nov 2, 2021

07:01AM EDT Cogent Biosciences to Present Virtually at Jefferies London Healthcare PR Newswire

Oct 11, 2021

10:51AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021 Benzinga

06:14AM EDT HC Wainwright & Co. Initiates Coverage On Cogent Biosciences with Buy Rating, Announces Price Target of $25 Benzinga

Oct 7, 2021

09:23AM EDT Cogent Presents New Data Showing Bezuclastinib As Differentiated KIT Inhibitor With Minimal Brain Penetration RTTNews

09:05AM EDT Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as PR Newswire

Oct 1, 2021

07:02AM EDT Cogent Biosciences Fo Present Preclinical Data On Bezuclastinib At AACR-NCI-EORTC Conference Oct. 7 Benzinga

07:01AM EDT Cogent Biosciences to Present Preclinical Data on Bezuclastinib at PR Newswire

Aug 16, 2021

07:24AM EDT Cogent Biosciences Q2 EPS $(0.43) Benzinga

07:03AM EDT Cogent Biosciences Q2 Net Loss $16.5 Mln Vs. Net Loss $7.4 Mln Last Year RTTNews

07:01AM EDT Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 PR Newswire

Aug 9, 2021

08:54AM EDT Cogent Biosciences Sponsored Study Titled '(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis' Posted To ClinicalTrials.Gov; Study Is Recruiting Benzinga

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Aug 3, 2021

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 21, 2021

11:53AM EDT Cogent Biosciences Granted Orphan Designation For 3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5- carboxamide Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 13, 2021

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jun 29, 2021

07:01AM EDT Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare PR Newswire

May 26, 2021

07:01AM EDT Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021 PR Newswire

May 12, 2021

07:13AM EDT Cogent Biosciences Q1 Net Loss $11.7 Mln Vs. Net Loss $6.1 Mln Last Year RTTNews

07:03AM EDT Cogent Biosciences Q1 EPS $(0.34) Up From $(0.81) YoY Benzinga

07:01AM EDT Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 PR Newswire

May 3, 2021

07:10AM EDT Cogent Biosciences Appoints Evan Kearns As Chief Legal Officer RTTNews

Apr 6, 2021

07:01AM EDT Cogent Biosciences Announces Creation of Cogent Research Team PR Newswire

Mar 16, 2021

07:19AM EDT Cogent Biosciences Q4 Sales $7.87M Down From $22.50M YoY Benzinga

07:08AM EDT Cogent Biosciences Q4 Net Loss $11.3 Mln Vs Net Income $2.3 Mln Last Year RTTNews

07:02AM EDT Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial PR Newswire

Feb 22, 2021

07:01AM EST Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to PR Newswire

Feb 18, 2021

07:01AM EST Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global PR Newswire

Feb 11, 2021

07:01AM EST Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology PR Newswire

Dec 23, 2020

10:07AM EST Benzinga's Top Upgrades, Downgrades For December 23, 2020 Benzinga

06:50AM EST Piper Sandler Initiates Coverage On Cogent Biosciences with Overweight Rating, Announces Price Target of $22 Benzinga

Dec 16, 2020

11:25AM EST Benzinga's Top Upgrades, Downgrades For December 16, 2020 Benzinga

07:43AM EST SVB Leerink Initiates Coverage On Cogent Biosciences with Outperform Rating, Announces Price Target of $20 Benzinga

Dec 4, 2020

05:17PM EST Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock PR Newswire

Dec 1, 2020

11:09PM EST Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of PR Newswire

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 30, 2020

04:01PM EST Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common PR Newswire

04:01PM EST Cogent Biosciences Announces $60M Public Offering Benzinga

07:01AM EST Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer PR Newswire

Nov 20, 2020

08:06AM EST The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga

07:01AM EST Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual PR Newswire

Nov 18, 2020

09:10AM EST Cogent Biosciences Announces Final Results From PLX9486 Phase 1/2 Study In Advanced GIST Patients At CTOS 2020 Benzinga

09:07AM EST Cogent Biosciences Announces Final Results From PLX9486 Phase 1/2 Study In Advanced GIST Patients RTTNews

09:01AM EST Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in PR Newswire

Nov 12, 2020

04:31PM EST Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare PR Newswire

Nov 9, 2020

07:30AM EST Cogent Biosciences Q3 EPS $(5.07) Down From $(1.56) YoY, Sales $312.00K Down From $1.02M YoY Benzinga

07:10AM EST Cogent Biosciences Q3 Loss/shr $5.07 Vs. Loss/shr $1.56 Last Year RTTNews

07:01AM EST Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides PR Newswire

Nov 6, 2020

02:45PM EST Stocks Trading Near 52-Week Lows On Friday, Nov. 6, 2020: ASRT, KBLMU, PNRG, YGMZ, APRE, UHT, LAIX, CLI, CORR, ANIP, CCOI, KBLM, NYC, UTL, PEI, TIG, EYEG, PVL, ZSAN, TTNP, NBRV, SFT, WPG, IFS, COGT, LMNL, PRFX, GBT, FNHC, ASMB, EPZM, UCL Benzinga

Nov 5, 2020

07:01AM EST Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare PR Newswire

Oct 26, 2020

07:07AM EDT Cogent Biosciences Announces Andrew Robbins CEO Benzinga

07:01AM EDT Cogent Biosciences Appoints Andrew Robbins As President And CEO RTTNews

07:01AM EDT Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer PR Newswire

Oct 14, 2020

08:31AM EDT Ladenburg Thalmann Initiates Coverage On Cogent Biosciences with Buy Rating, Announces Price Target of $4 Benzinga